Cubicin and Lofibra Capsules

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Before receiving DAPTOmycin, tell your doctor if you are taking fenofibrate. Both of these medications can cause injury to the muscles, and the risk may be increased when they are used together. If your doctor does prescribe DAPTOmycin, you may need to stop taking fenofibrate temporarily while you are being treated with DAPTOmycin, and you may need regular blood tests to monitor for possible muscle damage. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness while taking the medications, especially if these symptoms are accompanied by fever or dark colored urine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: There is some theoretical concern regarding the potential for additive musculoskeletal toxicity during coadministration of daptomycin and other drugs associated with myopathy, such as fibric acid derivatives. In animals, daptomycin has been associated with skeletal muscle effects characterized by degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). Elevations in serum CPK were also reported more frequently in daptomycin-treated patients than in comparator-treated patients (2.8% vs. 1.8%) in phase 3 clinical trials. Similarly, fibrates are known to occasionally cause myopathy manifested as muscle pain and/or weakness in association with grossly elevated levels of CPK. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria. Myopathy has not been reported in clinical trials of daptomycin.

MANAGEMENT: Due to the limited nature of existing data, consideration should be given to temporarily suspending use of fibrates in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

Cubicin

Generic Name: daptomycin

Brand name: Cubicin, Cubicin RF

Synonyms: n.a.

What is Cubicin?

Lofibra Capsules

Generic Name: fenofibrate

Brand name: Antara, Fenoglide, Lipofen, Tricor, Triglide, Lipidil Micro, Dom-Fenofibrate, Lipidil Supra, Lofibra, Lipidil EZ

Synonyms: Fenofibrate, Fenofibrate and Derivatives

What is Lofibra Capsules?